Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Troriluzole - Biohaven Pharmaceuticals

Next Previous
Drug Profile

Troriluzole - Biohaven Pharmaceuticals

Alternative Names: BHV-4157; BHV-4157a; Dazluma; FC 4157; trigriluzole; Trigriluzole-Biohaven Pharmaceuticals; Troriluzole-hydrochloride

Latest Information Update: 26 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Yale University
  • Developer Biohaven Pharmaceutical Holding Company; Biohaven Pharmaceuticals; Global Coalition for Adaptive Research; National Cancer Institute (USA); Rutgers Cancer Institute of New Jersey
  • Class Acetamides; Amines; Antidementias; Antineoplastics; Anxiolytics; Behavioural disorder therapies; Benzothiazoles; Fluorinated hydrocarbons; Neuroprotectants; Peptides; Small molecules
  • Mechanism of Action Excitatory amino acid antagonists; Glutamate release inhibitors; Voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinocerebellar degeneration
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Spinocerebellar degeneration
  • Phase III Obsessive-compulsive disorders
  • Phase II/III Alzheimer's disease; Glioblastoma
  • Phase II Malignant melanoma
  • No development reported Lymphoma; Solid tumours
  • Discontinued Anxiety disorders

Most Recent Events

  • 14 May 2025 Biohaven Pharmaceuticals anticipates a meeting with the FDA advisory committee to discuss troriluzole's potential for Spinocerebellar degeneration
  • 14 May 2025 Biohaven Pharmaceuticals completes the FDA mid-cycle review meeting and regulatory inspections for troriluzole for Spinocerebellar degeneration
  • 14 May 2025 Biohaven Pharmaceuticals expects the FDA's decision regarding the NDA of troriluzole for Spinocerebellar ataxia in USA, in 4Q 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top